Mylan lowers outlook after Q2 earnings, sales miss estimates

This article was originally published here

Shares in Mylan (NSDQ:MYL) fell today after the pharmaceutical company missed expectations on Wall Street with its second-quarter financial results.

The Canonsburg, Penn.-based company posted profits of $37.5 million, or 7¢ per share, on sales of $2.8 billion for the three months ended June 30, representing a bottom-line loss of -87.4% on a sales loss of 5% compared with the same period last year.

Get the full story at our sister site, Drug Delivery Business News.

The post Mylan lowers outlook after Q2 earnings, sales miss estimates appeared first on MassDevice.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply